Literature DB >> 8617424

Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor.

M Mise1, S Arii, H Higashituji, M Furutani, M Niwano, T Harada, S Ishigami, Y Toda, H Nakayama, M Fukumoto, J Fujita, M Imamura.   

Abstract

Hepatocellular carcinoma (HCC) is a typical hypervascular tumor. However, the relationship between the vascularity of HCC and the expression of angiogenic factors has not been investigated. In addition, no detailed studies have examined the possible involvement of angiogenic factors in the grade of malignancy of HCC. The aim of this study was to determine which angiogenic factors regulate tumor angiogenesis and contribute to the invasive ability of liver tumors, especially of HCC. Northern blot analysis was used to examine the transcriptional expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF), and acidic FGF in resected surgical specimens (20 HCC and 9 metastatic liver tumors). Correlations between messenger RNA (mRNA) expression and arteriographic findings, as well as histopathological findings, were evaluated. Immunohistochemistry was performed to identify the localization of cells expressing VEGF in HCC. Higher levels of VEGF mRNA were observed in 12 of 20 HCC and 2 of 9 metastatic liver tumors than in corresponding nontumorous tissues. The degree of VEGF mRNA expression was significantly correlated with the intensity of tumor staining in angiograms (P<.01). On immunohistochemical observation, VEGF protein was intensely detected in HCC cells. Furthermore, basic FGF mRNA was detected in 9 of 20 HCC and was related to the capsular infiltration of cancer cells (P<.05). In contrast, no significant difference was observed in the very low levels of acidic FGF mRNA found in the tumorous and nontumorous portions of the liver. In conclusion, these results suggest that VEGF contributes to angiogenesis of liver tumors, whereas basic FGF may be involved in the invasion of HCC into the surrounding tissues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617424     DOI: 10.1053/jhep.1996.v23.pm0008617424

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  77 in total

Review 1.  Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.

Authors:  L V Klotz; M E Eichhorn; B Schwarz; H Seeliger; M K Angele; K-W Jauch; Christiane J Bruns
Journal:  Langenbecks Arch Surg       Date:  2012-03-14       Impact factor: 3.445

Review 2.  Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2010-05-27       Impact factor: 3.402

3.  Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Kyle D Holen; Donald W Northfelt; Henry C Pitot; Joel Picus; Patrick J Flynn; Charles Erlichman
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

Review 4.  Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.

Authors:  Mohamed Bouattour; Audrey Payancé; Johanna Wassermann
Journal:  World J Hepatol       Date:  2015-09-18

5.  Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients.

Authors:  Hatem A El-mezayen; Hossam Darwish
Journal:  Tumour Biol       Date:  2014-04-01

6.  Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma.

Authors:  M J Gorrin-Rivas; S Arii; A Mori; Y Takeda; M Mizumoto; M Furutani; M Imamura
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

7.  Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization.

Authors:  Hiroshi Okano; Katsuya Shiraki; Yutaka Yamanaka; Hidekazu Inoue; Tomoyuki Kawakita; Yukiko Saitou; Yumi Yamaguchi; Naoyuki Enokimura; Keiichi Ito; Norihiko Yamamoto; Kazushi Sugimoto; Kazumoto Murata; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

8.  Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues.

Authors:  Geertu Deli; Can-Hao Jin; Rong Mu; Song Yang; Yue Liang; De Chen; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

9.  Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL).

Authors:  Hisashi Hidaka; Namiki Izumi; Takeshi Aramaki; Masafumi Ikeda; Yoshitaka Inaba; Kazuho Imanaka; Takuji Okusaka; Susumu Kanazawa; Shuichi Kaneko; Shinichi Kora; Hiroya Saito; Junji Furuse; Osamu Matsui; Tatsuya Yamashita; Osamu Yokosuka; Satoshi Morita; Hitoshi Arioka; Masatoshi Kudo; Yasuaki Arai
Journal:  Med Oncol       Date:  2019-05-03       Impact factor: 3.064

Review 10.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.